Facebook icon Twitter icon Forward icon

Warning over Lucozade sugar reduction

People who rely on Lucozade to treat hypos are being urged to check the labels of the energy drink as the amount of sugar is being halved.

The new formula, which will apply to all Lucozade flavours as well as the original, will be implemented from April 2017. To read more, click here

Diabetes.co.uk makes Sunday Times ‘disruptor’ list for low carb work

The team behind Europe’s largest diabetes community has been named in a prestigious Sunday Times list for disrupting type 2 diabetes treatment globally through a low carb, high fat approach.

Diabetes.co.uk was recognised as one of the top 100 disruptors of our time thanks to its pioneering Low Carb Program, which has seen the reversal of thousands of cases of type 2 diabetes.

To read more, click here

Diabetes consultant group launch empagliflozin audit

Diabetes teams are being invited to take part in a national audit of empagliflozin (Jardiance) launched by the Association of British Clinical Diabetologists (ABCD).

It now means that the organisation is auditing all three from the new class of diabetes drug, SGLT2 inhibitors. To read more, click here

Intensive glucose control can reduce kidney and eye events

Better intensive glucose control over five years can significantly reduce kidney and eye events in people with type 2 diabetes, research has found.

Although it was already known that intensive glucose control can help to prevent complications in adults with the condition, the research team wanted to find out exactly how blood sugar levels can also affect the risk of microvascular events.

To read more, click here

Type 2 drug semaglutide found to reduce HbA1C levels

The type 2 drug semaglutide reduces HbA1C levels, helps weight loss and results in fewer hypoglycaemic episodes than insulin glargine, according to new research.

To read more, click here.